

Article of Significant Interest Selected from This Issue by the Editors

SLAMF7 Signaling and Mechanism of Action of Elotuzumab, a Therapeutic Antibody against Multiple Myeloma

SLAMF7 is a SLAM family receptor expressed on natural killer (NK) cells and other immune cells. It is also highly expressed on multiple myeloma (MM) cells and is the target for a therapeutic antibody against MM, elotuzumab. Guo et al. (p. 41–51) show that SLAMF7 signaling is compromised in MM cells, due to the absence of the phosphatase CD45. This feature may explain why elotuzumab controls MM by an indirect mechanism, involving activation of other immune cells such as NK cells.